Back to Search Start Over

Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit.

Authors :
Deshmukh H
Wilmot EG
Gregory R
Barnes D
Narendran P
Saunders S
Furlong N
Kamaruddin S
Banatwalla R
Herring R
Kilvert A
Patmore J
Walton C
Ryder REJ
Sathyapalan T
Source :
Diabetes care [Diabetes Care] 2020 Sep; Vol. 43 (9), pp. 2153-2160. Date of Electronic Publication: 2020 Jul 15.
Publication Year :
2020

Abstract

Objective: The FreeStyle Libre (FSL) flash glucose-monitoring device was made available on the U.K. National Health Service (NHS) drug tariff in 2017. This study aims to explore the U.K. real-world experience of FSL and the impact on glycemic control, hypoglycemia, diabetes-related distress, and hospital admissions.<br />Research Design and Methods: Clinicians from 102 NHS hospitals in the U.K. submitted FSL user data, collected during routine clinical care, to a secure web-based tool held within the NHS N3 network. The t and Mann-Whitney U tests were used to compare the baseline and follow-up HbA <subscript>1c</subscript> and other baseline demographic characteristics. Linear regression analysis was used to identify predictors of change in HbA <subscript>1c</subscript> following the use of FSL. Within-person variations of HbA <subscript>1c</subscript> were calculated using [Formula: see text].<br />Results: Data were available for 10,370 FSL users (97% with type 1 diabetes), age 38.0 (±18.8) years, 51% female, diabetes duration 16.0 (±49.9) years, and BMI of 25.2 (±16.5) kg/m <superscript>2</superscript> (mean [±SD]). FSL users demonstrated a -5.2 mmol/mol change in HbA <subscript>1c</subscript> , reducing from 67.5 (±20.9) mmol/mol (8.3%) at baseline to 62.3 (±18.5) mmol/mol (7.8%) after 7.5 (interquartile range 3.4-7.8) months of follow-up ( n = 3,182) ( P < 0.0001). HbA <subscript>1c</subscript> reduction was greater in those with initial HbA <subscript>1c</subscript> ≥69.5 mmol/mol (>8.5%), reducing from 85.5 (±16.1) mmol/mol (10%) to 73.1 (±15.8) mmol/mol (8.8%) ( P < 0.0001). The baseline Gold score (score for hypoglycemic unawareness) was 2.7 (±1.8) and reduced to 2.4 (±1.7) ( P < 0.0001) at follow-up. A total of 53% of those with a Gold score of ≥4 at baseline had a score <4 at follow-up. FSL use was also associated with a reduction in diabetes distress ( P < 0.0001). FSL use was associated with a significant reduction in paramedic callouts and hospital admissions due to hypoglycemia and hyperglycemia/diabetic ketoacidosis.<br />Conclusions: We show that the use of FSL was associated with significantly improved glycemic control and hypoglycemia awareness and a reduction in hospital admissions.<br /> (© 2020 by the American Diabetes Association.)

Details

Language :
English
ISSN :
1935-5548
Volume :
43
Issue :
9
Database :
MEDLINE
Journal :
Diabetes care
Publication Type :
Academic Journal
Accession number :
32669277
Full Text :
https://doi.org/10.2337/dc20-0738